TY - JOUR AU - Mehdi Nouraie, AU - Janet S. Lee, AU - Yingze Zhang, AU - Tamir Kanias, AU - Xuejun Zhao, AU - Zeyu Xiong, AU - Timothy B. Oriss, AU - Qilu Zeng, AU - Gregory J. Kato, AU - J. Simon R. Gibbs, AU - Mariana E. Hildesheim, AU - Vandana Sachdev, AU - Robyn J. Barst, AU - Roberto F. Machado, AU - Kathryn L. Hassell, AU - Jane A. Little, AU - Dean E. Schraufnagel, AU - Lakshmanan Krishnamurti, AU - Enrico Novelli, AU - Reda E. Girgis, AU - Claudia R. Morris, AU - Erika Berman Rosenzweig, AU - David B. Badesch, AU - Sophie Lanzkron, AU - Oswaldo L. Castro, AU - Jonathan C. Goldsmith, AU - Victor R. Gordeuk, AU - Mark T. Gladwin, PY - 2013/02/28 Y2 - 2024/03/28 TI - The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe JF - Haematologica JA - haematol VL - 98 IS - 3 SE - Articles DO - 10.3324/haematol.2012.068965 UR - https://haematologica.org/article/view/6602 SP - 464-472 AB - The intensity of hemolytic anemia has been proposed as an independent risk factor for the development of certain clinical complications of sickle cell disease, such as pulmonary hypertension, hypoxemia and cutaneous leg ulceration. A composite variable derived from several individual markers of hemolysis could facilitate studies of the underlying mechanisms of hemolysis. In this study, we assessed the association of hemolysis with outcomes in sickle cell anemia. A hemolytic component was calculated by principal component analysis from reticulocyte count, serum lactate dehydrogenase, aspartate aminotransferase and total bilirubin concentrations in 415 hemoglobin SS patients. Association of this component with direct markers of hemolysis and clinical outcomes was assessed. As primary validation, both plasma red blood cell microparticles and cell-free hemoglobin concentration were higher in the highest hemolytic component quartile compared to the lowest quartile (P≤0.0001 for both analyses). The hemolytic component was lower with hydroxyurea therapy, higher hemoglobin F, and alpha-thalassemia (P≤0.0005); it was higher with higher systemic pulse pressure, lower oxygen saturation, and greater values for tricuspid regurgitation velocity, left ventricular diastolic dimension and left ventricular mass (all P